Veracyte Inc reports results for the quarter ended in December - Earnings Summary

Veracyte

23/02/2024 03:02

* Veracyte Inc  VCYT.OQ  reported a quarterly adjusted loss
of 39
cents​​ per share for the quarter ended in December, lower than
the same quarter last year, when the company reported EPS of -5
cents.  The mean expectation of nine analysts for the quarter
was for a loss of 9 cents per share. Wall Street expected
results to range from -14 cents to -6 cents per share.
    * Revenue rose 22.3% to $98.20 million from a year ago;
analysts
expected $91.96 million. 
    * Veracyte Inc's reported EPS for the quarter was a loss
of 39
cents​.
    * The company reported a quarterly loss of $28.29 million.
    * Veracyte Inc shares had fallen by 10.8% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3.9%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Veracyte Inc is
$33.00 
This summary was machine generated from LSEG data February 23 at
03:01 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.09          -0.39          Missed
 Sep. 30 2023      -0.15          -0.41          Missed
 Jun. 30 2023      -0.15          -0.12          Beat
 Mar. 31 2023      -0.13          -0.11          Beat